Catalyst Biosciences Inc (CBIO.OQ)
CBIO.OQ on NASDAQ Stock Exchange Capital Market
10.50USD
9:25pm IST
10.50USD
9:25pm IST
Change (% chg)
$0.13 (+1.25%)
$0.13 (+1.25%)
Prev Close
$10.37
$10.37
Open
$10.44
$10.44
Day's High
$10.58
$10.58
Day's Low
$10.26
$10.26
Volume
37,641
37,641
Avg. Vol
95,619
95,619
52-wk High
$37.00
$37.00
52-wk Low
$3.13
$3.13
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 0.01 | -0.561 |
| FY 2017 | Dec '17 | 0.32 | -1.261 |
| Sep '17 | 0.32 | -1.344 | |
| Jun '17 | 0.11 | -2.534 | |
| Mar '17 | 0.27 | -4.567 | |
| FY 2016 | Dec '16 | 0.07 | -4.679 |
| Sep '16 | 0.11 | -6.040 | |
| Jun '16 | 0.11 | -6.333 | |
| Mar '16 | 0.11 | -4.714 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 3 | 0.28 | 0.75 | 0.00 | 2.30 |
| Quarter Ending Sep-18 | 3 | 0.10 | 0.30 | 0.00 | -- |
| Year Ending Dec-18 | 3 | 1.05 | 2.36 | 0.01 | 0.90 |
| Year Ending Dec-19 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 3 | -0.62 | -0.45 | -0.81 | -0.62 |
| Quarter Ending Sep-18 | 3 | -0.72 | -0.59 | -0.87 | -0.89 |
| Year Ending Dec-18 | 3 | -2.75 | -2.36 | -3.27 | -4.28 |
| Year Ending Dec-19 | 3 | -3.09 | -2.41 | -3.96 | -3.18 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 30.95 | 32.74 | |
| P/E High - Last 5 Yrs. | -- | 40.70 | 45.73 | |
| P/E Low - Last 5 Yrs. | -- | 23.63 | 24.23 | |
| Beta | 1.35 | 0.89 | 0.88 | |
| Price to Sales (TTM) | 43.72 | 3.94 | 5.71 | |
| Price to Book (MRQ) | 0.81 | 4.81 | 5.37 | |
| Price to Tangible Book (MRQ) | 0.81 | 5.61 | 6.94 | |
| Price to Cash Flow (TTM) | -- | 22.91 | 23.32 | |
| % Owned Institutions | 33.39 | 1.21 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.56 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 1.57 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 4.47 | 5.32 | |
| Payout Ratio(TTM) | -- | 45.35 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 1.83 | 2.24 | 7.89 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 28.90 | 4.83 | 5.68 | |
| Sales - 5 Yr. Growth Rate | -66.71 | 10.08 | 10.33 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 59.98 | 16.38 | 19.38 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 43.85 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.88 | 10.78 | |
| Capital Spending - 5 Yr. Growth Rate | -20.03 | 15.52 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.12 | 2.19 |
| Current Ratio (MRQ) | 4.23 | 2.90 | 2.98 |
| LT Debt to Equity (MRQ) | 0.00 | 9.88 | 12.19 |
| Total Debt to Equity (MRQ) | 19.01 | 13.86 | 16.46 |
| Interest Coverage (TTM) | -32.83 | 35.89 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 54.81 | 54.46 | |
| Gross Margin - 5 Yr. Avg. | -- | 52.15 | 52.22 | |
| EBITD Margin (TTM) | -3,698.75 | -- | -- | |
| EBITD - 5 Yr. Avg | -82.54 | 18.57 | 10.98 | |
| Operating Margin (TTM) | -3,745.02 | 14.36 | 4.74 | |
| Operating Margin - 5 Yr. Avg. | -96.22 | 14.52 | 6.41 | |
| Pre-Tax Margin (TTM) | -3,298.22 | 14.82 | 5.58 | |
| Pre-Tax Margin - 5 Yr. Avg. | -88.84 | 14.91 | 6.83 | |
| Net Profit Margin (TTM) | -3,298.22 | 11.08 | 1.88 | |
| Net Profit Margin - 5 Yr. Avg. | -88.67 | 11.20 | 3.10 | |
| Effective Tax Rate (TTM) | -- | 23.16 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.42 | 23.95 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 56,200 | 938,104,133 | 846,855,612 | |
| Net Income/Employee (TTM) | -1,853,600 | 110,371,237 | 99,619,380 | |
| Receivable Turnover (TTM) | 1.88 | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | -- | 2.59 | 3.35 | |
| Asset Turnover (TTM) | 0.01 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -38.28 | 11.40 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -9.94 | 12.91 | 12.32 | |
| Return on Investment (TTM) | -68.74 | 14.84 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -12.47 | 16.88 | 16.11 | |
| Return on Equity (TTM) | -83.55 | 16.34 | 16.08 | |
| Return on Equity - 5 Yr. Avg. | -16.87 | 17.98 | 17.41 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -77.20 | -8.63 | -66.71 |
| EPS (TTM) % | 56.50 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Catalyst Biosciences Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Catalyst Biosciences Reports Q1 Loss Per Share $0.56
- BRIEF-Catalyst Biosciences Receives $1.5 Million For Neuronal Nicotinic Receptor Asset
- BRIEF-Catalyst Biosciences Provides Corporate Update
- BRIEF-Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D
- BRIEF-Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share
Institutional Holders
| % Shares Owned: | 80.17% |
| # of Holders: | 66 |
| Total Shares Held: | 9,568,021 |
| 3 Mo. Net Change: | 5,532,784 |
| # New Positions: | 29 |
| # Closed Positions: | 7 |
| # Increased Positions: | 51 |
| # Reduced Positions: | 10 |
| # Net Buyers: | 41 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.